studies on retatrutide Would love to hear any questions you guys have regarding these studies!?!, Sources, 1. https://pubmed.ncbi.nlm.nih.gov/37366315/. The New England Journal of Medicine, 2023, 2. Retatrutide 10mg – Triple Agonist

GLP-1 medications improve insulin sensitivity and reduce hyperinsulinemia, shifting the hormonal environment away from growth-factorrich conditions that may favor lesion survival

All glucagon-like peptide-1 receptor agonists (GLP-1 RAs) licensed for type 2 diabetes mellitus (T2DM) are facing a national shortage, the government has said

Dan Skovronsky, Eli Lillys chief scientific and medical officer, told NBC News that retatrutide is attempting to harness the bodys own mechanisms that metabolize food and tell the body when to stop eating

It might result in new thinking that goes beyond simply losing pounds and focuses on more health in general

Alterations of Gut Microbiota in IBS Human microbiota comprises trillions of microorganisms, most of which coexist in the gastrointestinal tract (Krautkramer et al., 2021)

My hope is that by explaining, and potentially convincing you of, their inevitability and the health inequity that will arise from delaying coverage, the conversation shifts away from should these be covered? to how do we ensure everyone who needs them is covered as soon as possible? How do we, collectively, best fight for patient access to these new revolutionary treatments